Log in
NASDAQ:ADVM

Adverum Biotechnologies Stock Forecast, Price & News

$12.38
-0.45 (-3.51 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.07
Now: $12.38
$13.08
50-Day Range
$11.58
MA: $13.90
$18.70
52-Week Range
$4.96
Now: $12.38
$26.98
Volume6.73 million shs
Average Volume1.43 million shs
Market Capitalization$998.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Read More
Adverum Biotechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$2.71 per share

Profitability

Net Income$-64,490,000.00

Miscellaneous

Employees82
Market Cap$998.53 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$12.38
-0.45 (-3.51 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

How has Adverum Biotechnologies' stock price been impacted by COVID-19 (Coronavirus)?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADVM stock has increased by 33.7% and is now trading at $12.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Adverum Biotechnologies?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adverum Biotechnologies
.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) issued its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.06.
View Adverum Biotechnologies' earnings history
.

What price target have analysts set for ADVM?

9 brokers have issued 12-month price targets for Adverum Biotechnologies' shares. Their forecasts range from $17.00 to $36.00. On average, they expect Adverum Biotechnologies' stock price to reach $24.38 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 9,040,000 shares, a decline of 27.9% from the August 15th total of 12,530,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 6.6 days.
View Adverum Biotechnologies' Short Interest
.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Amarin (AMRN), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Chipotle Mexican Grill (CMG).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO & Director (Age 56)
  • Mr. Thomas Leung, Chief Financial Officer

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Versant Venture Management LLC (8.72%), RTW Investments LP (8.42%), Vanguard Group Inc. (4.77%), Orbimed Advisors LLC (4.08%), UBS Group AG (2.07%) and Goldman Sachs Group Inc. (1.42%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Leone D Patterson, Mehdi Gasmi and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies
.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, UBS Group AG, Orbimed Advisors LLC, WS Management Lllp, AQR Capital Management LLC, Versant Venture Management LLC, Rhenman & Partners Asset Management AB, and SG Americas Securities LLC. Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies
.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of America Corp DE, Assenagon Asset Management S.A., Artal Group S.A., Goldman Sachs Group Inc., Federated Hermes Inc., First Light Asset Management LLC, and RTW Investments LP. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $12.38.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $998.53 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.